Glaukos Corporation (GKOS)

NYSE

$245.67

-$0.31

(-0.13%)

Previous Close: ⁦$246.03⁩

Market Closed

Glaukos Corporation (GKOS) Live Price Chart

Last updated: ⁦2026-11-14 05:35:40⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

Glaukos Corporation (GKOS) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $245.67, with a market capitalization of $14.56B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $87.32 to $255.19. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$14.56B
Open	$246.20
Day's High	$248.99
Day's Low	$242.94
Previous Close	$246.03
Volume	446.37K
Average Volume	1.17M
P/E Ratio	--
52-Week High	$255.19
52-Week Low	$87.32
Dividend Yield	--
Earnings Date	--

Glaukos Corporation (GKOS) Latest Closing Stock Price

Glaukos Corporation (GKOS) last closed at $245.67 as of 2026-11-14 00:31:00, down 0.13% ($0.31) from the previous close of $246.03.

During the latest regular trading session, GKOS traded between $242.94 and $248.99, with a volume of 446.37K shares. The closing price was near the middle and near the upper end of its 52-week range.

Glaukos Corporation (GKOS) 7-Day Stock Price Change

Over the past seven days, Glaukos Corporation (GKOS) moved from $219.98 to $245.67, representing a gain of 11.68% ($25.69).

The stock traded between $218.77 and $250.40 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.

The average daily volume was 953.28 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

GKOS 52-Week Price Position

Position in Range: 94.3%

52W Low$87.32

52W High$255.19

GKOS is currently trading at $245.67, placing it 94.3% of the way from its 52-week low of $87.32 to its 52-week high of $255.19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Glaukos Corporation (GKOS)?

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Glaukos Corporation Information

Industry	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees	1,094
Exchange	NYSE
Company Website	https://www.glaukos.com

GKOS News

Latest news related to Glaukos Corporation and GKOS stock.

Massive2026/11/12
10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study
10x Genomics announced that Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics will use its Xenium platform in a 24-month breast cancer biomarker study analyzing tumor biopsies from 500 patients. The collaboration aims to identify biomarkers predicting treatment response to neoadjuvant therapy, potentially advancing personalized cancer diagnostics. TXG stock has surged 264.7% year-to-date, outperforming broader markets.
Read Full Article
Massive2026/11/12
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
AMN Healthcare (AMN) is well-positioned for growth driven by strong healthcare staffing demand, MSP opportunities, and technology investments, with Nurse and Allied revenues rising 27% in Q3. However, the stock faces headwinds from visa delays affecting international nurse placements, pricing pressures, and weakness in Physician and Technology segments. The company holds a Zacks Rank #3 (Hold) rating despite surging 140.5% year-to-date.
Read Full Article
Massive2026/11/12
Merit Medical Reports Strong Real-World Data for WRAPSODY Device
Merit Medical Systems announced positive real-world clinical data from its WRAPSODY Cell-Impermeable Endoprosthesis, demonstrating 92.7% six-month target lesion primary patency and 76.7% access circuit primary patency, both exceeding WAVE trial results. The device received FDA approval in December 2024 and is now being commercialized in the U.S., with ongoing registry studies expected to generate comprehensive clinical evidence supporting wider physician adoption in the growing dialysis access market.
Read Full Article
Massive2026/11/12
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
CONMED (CNMD) is positioned for growth through its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, supported by expanding surgical adoption and favorable legislation. However, the company faces near-term challenges including U.S. orthopedic weakness, tariff pressures, and OEM business volatility. 2026 EPS estimates were raised to $4.58 per share despite headwinds.
Read Full Article
Massive2026/11/11
Here's Why You Should Retain INSP Stock in Your Portfolio for Now
Inspire Medical Systems (INSP) is positioned for solid growth despite a 32.5% year-to-date stock decline. The company faces near-term headwinds from $120 million in annual coding and reimbursement disruptions, but benefits from strong Inspire V adoption, improved clinical evidence, and a new CPT code effective in 2028. Project Horizon initiatives are expected to support low-single-digit revenue growth in 2027, though GLP-1 adoption and international weakness remain concerns.
Read Full Article

Ways to Trade GKOS at MEXC

GKOS MEXC RealStocks

Own real GKOS shares through MEXC's regulated brokerage partner.

Suitable for long-term holding.

Own the actual shares
Receive dividends and voting rights
Buy fractional shares starting at $1

How to Buy Glaukos Corporation (GKOS) Stock on MEXC

Eligible investors can buy real shares of Glaukos Corporation (GKOS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for GKOS and Place Your Order

Open the RealStocks trading page and search for GKOS. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Glaukos Corporation (GKOS) stock price today?

Glaukos Corporation (GKOS) is currently trading at $245.67, down 0.13% ($0.31) from the previous close of $246.03. Intraday prices update in real time during regular trading hours.

2.Is GKOS stock going up or down today?

As of 2026-11-14 00:31:00, GKOS is trading at $245.67, down 0.13% ($0.31) from its previous close of $246.03. The stock has traded between $242.94 and $248.99 during today’s regular session. Past price movements do not guarantee future results.

3.What is GKOS pre-market price?

As of 2026-11-14 00:31:00, GKOS is trading at $247.98 in pre-market trading, up 0.79% ($1.95) from the previous close of $246.03. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is GKOS after-hours price?

As of 2026-11-14 00:31:00, GKOS is trading at $245.71 in after-hours trading, up 0.01% ($0.03) from the regular-session close of $245.67. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is GKOS stock trading now?

GKOS trades on the NYSE exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does GKOS sit relative to its 52-week high and low?

Over the past 52 weeks, GKOS has traded between a low of $87.32 and a high of $255.19. At $245.67, the stock is positioned 94.3% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Glaukos Corporation in?

Glaukos Corporation (GKOS) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Glaukos Corporation's market capitalization and where is it listed?

Glaukos Corporation is listed on the NYSE exchange with a market capitalization of $14.56B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is GKOS valued in terms of P/E ratio and EPS?

GKOS trades at a P/E ratio of --, based on trailing-twelve-month EPS of $-2.87. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Glaukos Corporation pay a dividend?

Glaukos Corporation pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Tesla, Inc.

TSLA

Micron Technology, Inc.

Top Gainers

Browse today's leading gainers in the US stock market

Onfolio Holdings Inc.

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

Compliance Disclosure and Data Source

Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to GKOS, including Stocks, Tokenized Stocks, and Stock Futures.

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

Anthropic (PRE): Win NVIDIA H200

Claim PRE points for guaranteed prizes up to $3K

Search Stocks

Popular

FCUV AKAN ONFO SLSN VTSI

GKOS Stock Calculator

Estimate the value between GKOS shares and USD.

GKOS Shares to USD

GKOS Shares

GKOS

USD

1.00 GKOS shares = 245.674 USD

Calculations are estimates based on the latest available price and are for reference only.

Glaukos Corporation (GKOS)

Summary

Key Market Data

Glaukos Corporation (GKOS) Latest Closing Stock Price

Glaukos Corporation (GKOS) 7-Day Stock Price Change

GKOS 52-Week Price Position

What is Glaukos Corporation (GKOS)?

Glaukos Corporation Information

GKOS News

10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study

Here's Why You Should Retain AMN Stock in Your Portfolio for Now

Merit Medical Reports Strong Real-World Data for WRAPSODY Device

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

Here's Why You Should Retain INSP Stock in Your Portfolio for Now

Ways to Trade GKOS at MEXC

GKOS MEXC RealStocks

How to Buy Glaukos Corporation (GKOS) Stock on MEXC

Frequently Asked Questions (FAQ)

Explore More US Stocks

Largest Market Cap

Most Actively Traded

Top Gainers

Top 5 Cryptocurrencies

Compliance Disclosure and Data Source

Disclaimer

Search Stocks

GKOS Stock Calculator